Catalog No.: PC-21698Not For Human Use, Lab Use Only.
Fraisinib is a specific and effective inhibitor of glycyl-tRNA synthetase 1 (GARS1), suppresses the synthesis of Ap4A by GARS1 and displays strong anti-tumoral potential.
Fraisinib is a specific and effective inhibitor of glycyl-tRNA synthetase 1 (GARS1), suppresses the synthesis of Ap4A by GARS1 and displays strong anti-tumoral potential.
GARS1 is an enzyme that is essential in protein synthesis by charging tRNA with glycine amino acid.
Fraisinib treatment (10 uM) induces caspase cascade activation, cell cycle arrests at the G0/G1 phase, and apoptosis activation and invasiveness inhibition in A549 cells.
Fraisinib shows no cytotoxic effect on lymphocytes (peripheral blood mononuclear cells, PBMCs) in the 0.1-300 µM concentration range.
Fraisinib (125 mg/kg BW) reduced the size and the weight of tumors in vivo in immunodeficient CD-1 nude mice (Crl:CD1-Foxn1nu).
Fraisinib (0.1–20 µM) inhibited GARS1 activity dose-dependently.
Fraisinib can modulate different biological and molecular pathways related to GARS1 functions in a unique way.
